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The ‘‘built-in’’ adjuvant in a whole-microbe vaccine potentially triggers protective immunity. Coban et al. now
demonstrate that crude blood stage extract of the malaria parasite Plasmodium falciparum drives parasite-
specific immune responses via Hemozoin, a byproduct of heme detoxification, functioning as a TLR9 agonist
and, therefore, as a ‘‘built-in’’ adjuvant.There is compelling evidence that patho-
gens, including parasites that cause
chronic infections, often subvert the power
of protective immunity by harnessing regu-
latory T cells (Tregs). Treg function can be
a double-edged sword. On the one hand,
they contribute to maintenance of self-
tolerance by suppressing autoreactive
T cells. On the other hand, Tregs dampen
protective immunity, thereby favoring
chronic infections (Belkaid et al., 2002; Hi-
saeda et al., 2004).
The innate and adaptive immune system
uses two fundamentally different strategies
to recognize infectious invaders. The first
makes use of a limited number of germ-
line-encoded pattern recognition receptors
(PRRs), such as Toll-like receptors (TLRs),
that recognize—as ligand—unique path-
ogen-associated molecular structures
(PAMPs). The latter, however, uses ran-
domly and somatically generated clonally
expressed receptors (Takeda et al.,2003).
Dendritic cells (DCs) expressing TLRs
pilot both innate and adaptive immunity.Upon TLR-driven activation, DCs produce
proinflammatory and protective cytokines
that contribute to innate immunity. DCs
also couple the identity of the invader’s
antigens with its microbial origin. Piloting
of adaptive immunity largely occurs
through TLR-driven maturation of anti-
gen-presenting DCs (Palm and Medzhi-
tov, 2009). There is also compelling
evidence that ‘‘noninflammatory’’ anti-
gen-presenting DCs favor Treg formation
that, in turn, paralyzes DCs, whereas
highly activated DCs drive the generation
of CD4 and CD8 effector cells. Accord-
ingly, the interplay between DC-activated
T-effector/memory cells and dampening
Tregs determines the efficacy of adaptive
immunity.
People in malaria-endemic regions
gradually acquire protective immunity
against the parasite but only after re-
peated infection. This raises the question
as to whether plasmodium-derived anti-
gens are weakly immunogenic because
of a lack of a ‘‘built-in’’ adjuvant or dueto upregulated Tregs (Walther et al.,
2005). Of note, immune escape of malaria
parasites requires activation of Tregs, at
least in murine model systems (Hisaeda
et al., 2008). In terms of ‘‘built-in’’ adju-
vants, whether and how TLRs contribute
to the induction of protective antimalaria
immunity is not fully understood. In partic-
ular, the role of parasite DNA recognition
by TLR9 has been controversial (Coban
et al., 2005; Jaramillo et al., 2004; Par-
roche et al., 2007).
Because nucleic acid recognition by
TLRs—expressed in the phago-endoso-
mal membrane—have been viewed as
ligand specific, it came as a surprise to
learn that purified malaria pigment hemo-
zoin activates innate immune cells via
TLR9, i.e., functioned as TLR9 ligand (Co-
ban et al., 2005). Hemozoin is a heme poly-
mer produced in malaria as a byproduct of
the heme detoxification system and has
been implicated to activate macrophages
and DCs (Jaramillo et al., 2004). However,
according to Parroche et al., DNase7, January 21, 2010 ª2010 Elsevier Inc. 5
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Previewstreatment of crude hemozoin extracts
ablates its TLR9-mediated immune-stimu-
latory activity, suggesting that hemozoin
itself maybe immunologically inert. In
fact, their data implicated hemozoin crys-
tals as just a ‘‘carrier’’ to deliver malaria
DNA to TLR9 expressed in phago-endo-
somes (Parroche et al., 2007).
Probably stimulated by these conflict-
ing conclusions, Coban et al. have now
further analyzed the mechanism by which
TLR9 activates innate immune cells
during malaria infection. In this issue of
Cell Host & Microbe, they first report
that the immunogenicity of whole-para-
site vaccines against P. falciparum
involves hemozoin as ligand for host
TLR9 (Coban et al., 2010). At the molec-
ular and atomic level, they go on to
show that DNA-free hemozoin not only
directly binds to TLR9, but also induces
conformational changes of TLR9 equal
to those induced by the canonical
TLR9 ligand CpG-DNA. Furthermore,
TLR9 binding of hemozoin requires the
same binding motifs as that of CpG
DNA. Altogether, these data unequivo-
cally resolve the ‘‘TLR9-hemozoin’’
controversy.
In addition, the in-depth analyses of
Coban et al. dug out some unexpected6 Cell Host & Microbe 7, January 21, 2010 ª2observations. In various vaccination
protocols, synthetic (s)-hemozoin medi-
ated its robust adjuvant effect via
MyD88, a scaffold protein of TLR sig-
naling, but did not require TLR9- or
PRR-driven inflammasome activation,
suggesting that natural hemozoin prefer-
entially activates TLR9, whereas s-hemo-
zoin drives an as yet undefined receptor
in a MyD88-dependent manner. Counter-
intuitively, a new receptor puzzle has thus
been generated.
While this existing set of data primarily
focuses on natural hemozoin and its func-
tion as a TLR9-dependent ‘‘built-in’’ adju-
vant during whole-blood stage parasite
vaccination, it also raises questions that
now can be addressed. Given that Tregs
presumably drive chronic malaria infec-
tion, it would be interesting to learn
whether the TLR9 ligand hemozoin also
triggers Treg formation. A real surprise
would be if the yet unknown hemozoin-
sensing receptor comes into play for
Treg formation.REFERENCES
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Focal accumulations of mononuclear cells, called granulomas, are a hallmark of mycobacterial infections.
A common misconception is that granulomas are uniformly protective. In transparent zebrafish larvae
infected with Mycobacterium marinum, Volkman et al. demonstrate an interaction of mycobacteria with
epithelial cells that helps recruit macrophages to the granuloma as ‘‘feeder cells.’’Mycobacterial infections rank among
the diseases with the highest morbidity
and mortality worldwide. Mycobacterium
tuberculosis complex (Mtb) alone causes
8 million new cases of tuberculosis(TB) each year, with 20% of those infected
succumbing to disease.
The pathological hallmark of TB is the
granuloma, a focal accumulation of mac-
rophages and lymphocytes in variousstages of differentiation. The tubercle
(from the Latin word ‘‘tuberculum,’’ a small
knob or nodule) harbors mycobacteria in
different phases of replication and meta-
bolic distress. Granulomas are the visible
